Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-05 10:55 am Sale |
2024-09-30 | 13G | Nuvectis Pharma, Inc. NVCT |
Pontifax Management 4 GP (2015) Ltd. | 288,873 1.500% |
-628,527 (-68.51%) |
Filing History |
| 2024-02-28 08:37 am Purchase |
2023-12-31 | 13G | Nuvectis Pharma, Inc. NVCT |
Mosseri Marlio Charles | 2,595,000 15.000% |
214,824 (+9.03%) |
Filing History |
| 2024-02-06 08:47 am Purchase |
2023-12-31 | 13G | Nuvectis Pharma, Inc. NVCT |
Pontifax Management 4 GP (2015) Ltd. | 917,400 5.300% |
917,400 (New Position) |
Filing History |
| 2024-01-31 7:34 pm Purchase |
2023-12-31 | 13G | Nuvectis Pharma, Inc. NVCT |
Poradosu Enrique | 1,503,819 8.700% |
285,500 (+23.43%) |
Filing History |
| 2024-01-31 7:33 pm Purchase |
2023-12-31 | 13G | Nuvectis Pharma, Inc. NVCT |
Shemesh Shay | 1,491,955 8.600% |
286,090 (+23.72%) |
Filing History |
| 2024-01-30 9:01 pm Sale |
2023-12-31 | 13G | Nuvectis Pharma, Inc. NVCT |
Peters Thomas Phineas | 908,475 5.200% |
-39,183 (-4.13%) |
Filing History |
| 2023-04-03 08:15 am Purchase |
2022-02-04 | 13G | Nuvectis Pharma, Inc. NVCT |
Peters Thomas Phineas | 947,658 6.400% |
947,658 (New Position) |
Filing History |
| 2023-02-13 5:16 pm Purchase |
2022-12-31 | 13G | Nuvectis Pharma, Inc. NVCT |
Shemesh Shay | 1,205,865 8.200% |
1,205,865 (New Position) |
Filing History |
| 2023-02-13 5:15 pm Purchase |
2022-12-31 | 13G | Nuvectis Pharma, Inc. NVCT |
Poradosu Enrique | 1,218,319 8.300% |
1,218,319 (New Position) |
Filing History |
| 2023-01-09 10:19 am Purchase |
2022-12-30 | 13G | Nuvectis Pharma, Inc. NVCT |
Mosseri Marlio Charles | 2,380,176 16.300% |
977,620 (+69.70%) |
Filing History |
| 2022-03-28 6:46 pm Purchase |
2022-03-22 | 13G | Nuvectis Pharma, Inc. NVCT |
Mosseri Marlio Charles | 1,402,556 11.030% |
1,402,556 (New Position) |
Filing History |
| 2022-03-28 5:22 pm Purchase |
2022-03-17 | 13D | Nuvectis Pharma, Inc. NVCT |
BENTSUR RON | 2,728,700 21.460% |
2,728,700 (New Position) |
Filing History |
| 2022-02-15 5:18 pm Purchase |
2022-02-08 | 13G | Nuvectis Pharma, Inc. NVCT |
Mosseri Marlio Charles | 1,265,200 9.950% |
1,265,200 (New Position) |
Filing |